≤1cm非小细胞肺癌淋巴结清扫策略
摘要
常见的肺癌类型，约占所有肺癌病例的85%，其高发病率和高死亡率给公共卫生系统带来了重大挑战。早期发现和
有效治疗对于提高非小细胞肺癌患者的生存率至关重要。淋巴结清扫是治疗非小细胞肺癌的关键步骤，尽管关于淋
巴结清扫已有大量研究，但针对肿瘤直径≤1厘米的非小细胞肺癌患者的淋巴结清扫策略研究相对较少。本文首先
介绍了淋巴结清扫的微创技术，包括电视胸腔镜手术（VATS）和机器人辅助手术，这些技术具有创伤小、恢复快
等优点。随后，讨论了目前全球现有的淋巴结清扫方法，包括系统性淋巴结清扫（SND）和肺叶特异性淋巴结清
扫，并指出清扫方法的选择取决于患者的具体情况。文章还探讨了肿瘤直径≤1厘米时非小细胞肺癌的淋巴结转移
情况，强调了准确进行术前和术中淋巴结状态评估的重要性。通过对多项研究的分析，文章强调肿瘤实性成分比例
（CTR）和肿瘤位置是预测淋巴结转移的关键因素。此外，文章还讨论了术中冰冻切片病理检查在确定淋巴结状态
以及以磨玻璃影为主的早期非小细胞肺癌患者预后方面的作用。最后，文章总结了肿瘤直径≤1厘米的非小细胞肺
癌患者的淋巴结清扫策略，包括术前评估、术中冰冻切片病理检查以及淋巴结阳性判定等，并指出这些策略仍需通
过更多随机对照临床试验进行验证。
关键词
全文:
PDF参考
[1]Aberle DR, Adams AM, Berg CD, Black WC, Clapp
JD, Fagerstrom RM, et al. Reduced lung-cancer mortality
with low-dose computed tomographic screening. N Engl J
Med. 2011;365(5):395 - 409.
[2]Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT.
The eighth edition lung cancer stage classification. Chest.
2017;151(1):193 - 203.
[3]Goldstraw P, Crowley J, Chansky K, Giroux DJ,
Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer
Staging Project: proposals for the revision of the TNM
stage groupings in the forthcoming (seventh) edition of the
TNM classification of malignant tumours. J Thorac Oncol.
2007;2(8):706 - 714.
[4]Goldstraw P. Report on the international workshop
on intrathoracic staging. London, October 1996. Lung
Cancer. 1997;18(1):107 - 111.
[5]Izbicki JR, Passlick B, Pantel K, Blohmer JU,
Ruckdeschel JC, Dienemann H. Effectiveness of radical
systematic mediastinal lymphadenectomy in patients with
resectable non-small cell lung cancer: results of a prospective
randomized trial. Ann Surg. 1998;227(1):0.
[6]Wu YL, Huang ZF, Wang SY, Yang XN, Ou W. A
randomized trial of systematic nodal dissection in resectable
non-small cell lung cancer. Lung Cancer. 2002;36(1):1 - 6.
[7]Darling GE, Allen MS, Decker PA, Landreneau RJ,
Mckenna RJ Jr, Sloan JP, et al. Randomized trial of mediastinal
lymph node sampling versus complete lymphadenectomy
during pulmonary resection in the patient with N0 or N1 (less
than hilar) non-small cell carcinoma: results of the American
College of Surgery Oncology Group Z0030 Trial. J Thorac
Cardiovasc Surg. 2011;141(3):662 - 670.
[8]Allen MS, Darling GE, Pechet TT, Decker PA,
Landreneau RJ, Mckenna RJ Jr, et al. Morbidity and mortality
of major pulmonary resections in patients with early-stage
lung cancer: initial results of the randomized, prospective
ACOSOG Z0030 trial. Ann Thorac Surg. 2006;81(3):1013 -
1019; discussion 1019 - 1020.
[9]Hattori A, Matsunaga T, Takamochi K, Kato
T, Miyata Y, Matsumoto T, et al. Extent of mediastinal
nodal dissection in stage I non-small cell lung cancer with
a radiological pure-solid appearance. Eur J Surg Oncol.
2021;47(5):0.
[10]Sui QH, Yang HQ, Yin JC, Liu Y, Zhang X, Li
Y, et al. The comparison of Lobe-Specific or Systematic
Mediastinal Lymph Node Dissection for Early-Stage Lung
Adenocarcinoma With Consolidation Tumor Ratio Over 0.5.
Clin Lung Cancer. 2023;24(1):51 - 59.
Refbacks
- 当前没有refback。
